HAE

Business Context and Reporting Period

Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 29, 2002 (First Quarter of Fiscal 2003)
Business Overview: Haemonetics designs, manufactures, and markets automated blood processing systems. The company operates as a single segment, offering products for blood banks, red cell collection, surgical blood salvage, and plasma collection. Approximately 62% of revenues are generated internationally.

Key Financial Metrics

Note: Prior period debt figures are not explicitly detailed in the provided text for direct comparison, though current liabilities show notes payable and current maturities of $36,369 and long-term debt of $38,430 as of June 29, 2002.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 8.1% year-over-year. On a constant currency basis, revenue growth was 11.1%, driven by volume increases in Surgical, Blood Bank, Red Cell, and Plasma disposables.
• Profitability Decline: Net income decreased 31.9% to $6.8 million. This decline is primarily due to the absence of a $2.3 million cumulative effect of a change in accounting principle (SFAS 133 adoption) recorded in the prior year, which is not present in the current quarter.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 9.3% to $24.0 million, attributed to new product sales and marketing activities. Research and development remained relatively flat at $4.9 million.
• Product Mix Shift: Equipment revenues surged 95.5% to $4.8 million, driven by sales of platelet and plasma machines in Japan and Europe and the new ACP 215 system domestically. Disposable sales grew 4.1%.
• Currency Impact: Foreign exchange fluctuations negatively impacted reported revenue growth. The indexed hedge spot rates depreciated 8.9% compared to the prior year.

Guidance, Outlook, and Risks

• Outlook: Management does not provide specific forward-looking revenue or earnings guidance for the full year. They note that equipment sales are variable and offer no assurance that recent significant increases will continue.
• Capital Allocation: The company repurchased 868,200 shares of common stock for approximately $26.0 million during the quarter. These shares are held in treasury for employee benefit plans and corporate purposes.
• Liquidity: Working capital decreased by $30.2 million compared to the prior year, largely due to increased short-term borrowings and accrued expenses, offset by higher inventories and receivables. The company believes current sources of capital are sufficient for operations.
• Risks and Contingencies:
  • Foreign Exchange: 62% of revenues are in foreign currencies (primarily Euro and Yen). A 10% strengthening of the U.S. dollar could increase the fair value of forward contracts by $10.4 million, impacting results.
  • Regulatory and Market: Risks include regulatory changes, market acceptance of new products, and competitive pricing.
  • Contingent Obligations: The company has potential earn-out payments of up to $4.1 million related to the Fifth Dimension acquisition and milestone payments of up to $14.5 million related to a pathogen inactivation technology agreement with Baxter Healthcare.

Investor Verification Checklist

• Accounting Change Impact: Verify the exclusion of the $2.3 million one-time gain from the prior year to accurately assess organic earnings performance.
• Inventory Build-up: Review the $7.4 million increase in inventory levels to ensure it aligns with demand forecasts and does not signal future write-downs.
• Equipment Sales Sustainability: Assess the durability of the 95.5% increase in equipment sales, given management's caution regarding the variable nature of these transactions.
• Currency Hedging Effectiveness: Monitor the impact of the 8.9% depreciation in indexed hedge spot rates on future revenue recognition.
• Debt Structure: Confirm the terms of the $74.8 million total debt, noting that nearly 100% is at fixed rates, mitigating interest rate risk.